179 related articles for article (PubMed ID: 38429609)
1. Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs.
Holzleitner N; Fischer S; Maniyankerikalam I; Beck R; Lapa C; Wester HJ; Günther T
EJNMMI Res; 2024 Mar; 14(1):23. PubMed ID: 38429609
[TBL] [Abstract][Full Text] [Related]
2. Introduction of a SiFA Moiety into the D-Glutamate Chain of DOTA-PP-F11N Results in Radiohybrid-Based CCK-2R-Targeted Compounds with Improved Pharmacokinetics In Vivo.
Holzleitner N; Günther T; Beck R; Lapa C; Wester HJ
Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558917
[TBL] [Abstract][Full Text] [Related]
3. Development of the First
Günther T; Holzleitner N; Di Carlo D; Urtz-Urban N; Lapa C; Wester HJ
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986687
[TBL] [Abstract][Full Text] [Related]
4. Investigation of the structure-activity relationship at the N-terminal part of minigastrin analogs.
Holzleitner N; Günther T; Daoud-Gadieh A; Lapa C; Wester HJ
EJNMMI Res; 2023 Jul; 13(1):65. PubMed ID: 37421545
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [
Günther T; Holzleitner N; Viering O; Beck R; Wienand G; Dierks A; Pfob CH; Bundschuh RA; Kircher M; Lapa C; Wester HJ
J Nucl Med; 2024 Jan; 65(1):33-39. PubMed ID: 37945383
[TBL] [Abstract][Full Text] [Related]
6. Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog
Sauter AW; Mansi R; Hassiepen U; Muller L; Panigada T; Wiehr S; Wild AM; Geistlich S; Béhé M; Rottenburger C; Wild D; Fani M
J Nucl Med; 2019 Mar; 60(3):393-399. PubMed ID: 30002107
[TBL] [Abstract][Full Text] [Related]
7. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
8. DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.
Klingler M; Summer D; Rangger C; Haubner R; Foster J; Sosabowski J; Decristoforo C; Virgolini I; von Guggenberg E
J Nucl Med; 2019 Jul; 60(7):1010-1016. PubMed ID: 30530828
[TBL] [Abstract][Full Text] [Related]
9. Cholecystokinin 2 Receptor Agonist
Rottenburger C; Nicolas GP; McDougall L; Kaul F; Cachovan M; Vija AH; Schibli R; Geistlich S; Schumann A; Rau T; Glatz K; Behe M; Christ ER; Wild D
J Nucl Med; 2020 Apr; 61(4):520-526. PubMed ID: 31519804
[TBL] [Abstract][Full Text] [Related]
10. Receptor-Mediated Melanoma Targeting with Radiolabeled α-Melanocyte-Stimulating Hormone: Relevance of the Net Charge of the Ligand.
Bapst JP; Eberle AN
Front Endocrinol (Lausanne); 2017; 8():93. PubMed ID: 28491052
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of cholecystokinin analogs in which the Asp-Phe-NH2 moiety has been replaced by a 3-amino-7-phenylheptanoic acid or a 3-amino-6-(phenyloxy)hexanoic acid.
Amblard M; Rodriguez M; Lignon MF; Galas MC; Bernad N; Artis-Noël AM; Hauad L; Laur J; Califano JC; Aumelas A
J Med Chem; 1993 Oct; 36(20):3021-8. PubMed ID: 7692048
[TBL] [Abstract][Full Text] [Related]
12. An assessment tumor targeting ability of (177)Lu labeled cyclic CCK analogue peptide by binding with cholecystokinin receptor.
Cho EH; Lim JC; Lee SY; Jung SH
J Pharmacol Sci; 2016 Jul; 131(3):209-14. PubMed ID: 27430985
[TBL] [Abstract][Full Text] [Related]
13. Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.
Zavvar TS; Hörmann AA; Klingler M; Summer D; Rangger C; Desrues L; Castel H; Gandolfo P; von Guggenberg E
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37052226
[TBL] [Abstract][Full Text] [Related]
14. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma.
Fröberg AC; de Jong M; Nock BA; Breeman WA; Erion JL; Maina T; Verdijsseldonck M; de Herder WW; van der Lugt A; Kooij PP; Krenning EP
Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1265-72. PubMed ID: 19266197
[TBL] [Abstract][Full Text] [Related]
15. Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2 receptor.
Lipiński PFJ; Garnuszek P; Maurin M; Stoll R; Metzler-Nolte N; Wodyński A; Dobrowolski JC; Dudek MK; Orzełowska M; Mikołajczak R
EJNMMI Res; 2018 Apr; 8(1):33. PubMed ID: 29663167
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors.
Charpentier B; Dor A; Roy P; England P; Pham H; Durieux C; Roques BP
J Med Chem; 1989 Jun; 32(6):1184-90. PubMed ID: 2724293
[TBL] [Abstract][Full Text] [Related]
17. Optimised labeling, preclinical and initial clinical aspects of CCK-2 receptor-targeting with 3 radiolabeled peptides.
Breeman WA; Fröberg AC; de Blois E; van Gameren A; Melis M; de Jong M; Maina T; Nock BA; Erion JL; Mäcke HR; Krenning EP
Nucl Med Biol; 2008 Nov; 35(8):839-49. PubMed ID: 19026945
[TBL] [Abstract][Full Text] [Related]
18. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]